Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / INCY
Stock rating
Incyte Genomics Inc (INCY) Stock Rating & Analysis
As of September 25, 2026, MELANY rates Incyte Genomics Inc 73 out of 100 (Highest Conviction). Its highest factor score is earnings track record at 94, and its lowest is macro fit at 50.
MELANY ratingRated 2026-09-25INCY · composite score
Why INCY scores 73/100
INCY's 8 factor scores run from 50 to 94, and 4 of them sit above its composite of 73. Here is how INCY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 17.5x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
- Gross margin 56%
- ROE 31%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +25%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 32 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How INCY compares
As of October 7, 2026, Incyte Genomics Inc is tied for 1st of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for INCY
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Incyte Genomics Inc sits in the Healthcare sector theme, which MELANY currently rates 44/100 for strength. Theme strength feeds INCY's momentum and catalyst factors above.
INCY trade plan (Pro)
MELANY has a full position plan for Incyte Genomics Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates INCY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Incyte Genomics Inc's 73/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about INCY
Is Incyte Genomics Inc (INCY) a buy?
As of 2026-09-25, MELANY rated Incyte Genomics Inc Highest Conviction with a composite score of 73/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Incyte Genomics Inc's MELANY score?
Incyte Genomics Inc (INCY) has a MELANY composite score of 73/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the INCY stock rating calculated?
MELANY scores INCY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Incyte Genomics Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Incyte Genomics Inc (INCY) Highest Conviction with a composite of 73/100 as of 2026-09-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the INCY stock price forecast?
MELANY does not publish price targets or forecasts for INCY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 73/100 across eight factors for Incyte Genomics Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is INCY stock overvalued or undervalued?
MELANY's valuation factor currently reads 56/100 for Incyte Genomics Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives INCY's read.
What price should I buy INCY at?
Rather than chasing the current price, MELANY computes a smart entry zone for INCY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying INCY stock?
The top risks MELANY currently flags for Incyte Genomics Inc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Incyte Genomics Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 89/100 for Incyte Genomics Inc, and earnings track record, at 94/100. The 73/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will INCY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 70/100 for INCY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this INCY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores INCY continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, INCY included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.